Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Humans Male Chemotaxis / drug effects Disease Progression Drug Resistance, Neoplasm Inflammation / drug therapy Lewis X Antigen / metabolism Myeloid Cells / drug effects Neoplasm Metastasis Prostate / drug effects Prostatic Neoplasms, Castration-Resistant / drug therapy Receptors, Androgen / metabolism Androgen Receptor Antagonists / pharmacology Antineoplastic Agents / pharmacology

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 23 05 2023
accepted: 28 09 2023
medline: 1 12 2023
pubmed: 17 10 2023
entrez: 16 10 2023
Statut: ppublish

Résumé

Inflammation is a hallmark of cancer

Identifiants

DOI: 10.1038/s41586-023-06696-z PMID: 37844613 PMC: PMC10686834
pubmed: 37844613
doi: 10.1038/s41586-023-06696-z
pii: 10.1038/s41586-023-06696-z
pmc: PMC10686834
doi:

Substances chimiques

CD14 protein, human 0
enzalutamide 93T0T9GKNU
ITGAM protein, human 0
Lewis X Antigen 0
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 0
Receptors, Androgen 0
Androgen Receptor Antagonists 0
Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1053-1061

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204 doi: 10.1158/2159-8290.CD-21-1059
Templeton, A. J. et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 120, 3346–3352 (2014).
pubmed: 24995769 doi: 10.1002/cncr.28890
Leibowitz-Amit, R. et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 25, 657–662 (2014).
pubmed: 24458472 pmcid: 4433513 doi: 10.1093/annonc/mdt581
Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12, 729 (2021).
pubmed: 33526794 pmcid: 7851155 doi: 10.1038/s41467-021-20935-9
Howard, R., Kanetsky, P. A. & Egan, K. M. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci. Rep. 9, 19673 (2019).
pubmed: 31873162 pmcid: 6928022 doi: 10.1038/s41598-019-56218-z
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338 doi: 10.3322/caac.21660
Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).
pubmed: 28034081 doi: 10.1200/JCO.2016.69.1584
Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
pubmed: 24831977 pmcid: 4418935 doi: 10.1016/S1470-2045(14)70189-5
Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020).
pubmed: 31774688 doi: 10.1200/JCO.19.01638
Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature https://doi.org/10.1038/s41586-018-0266-0 (2018).
doi: 10.1038/s41586-018-0266-0 pubmed: 29950727 pmcid: 6461206
Garcia, A. J. et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol. Cell. Biol. 34, 2017–2028 (2014).
pubmed: 24662052 pmcid: 4019050 doi: 10.1128/MCB.00090-14
Di Mitri, D. et al. Tumour-infiltrating Gr-1
pubmed: 25156255 doi: 10.1038/nature13638
Guo, C. et al. CD38 in advanced prostate cancers. Eur. Urol. 79, 736–746 (2021).
pubmed: 33678520 pmcid: 8175332 doi: 10.1016/j.eururo.2021.01.017
Lopez-Bujanda, Z. A. et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nat. Cancer 2, 803–818 (2021).
pubmed: 35122025 pmcid: 9169571 doi: 10.1038/s43018-021-00227-3
Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80–95 (2016).
pubmed: 26701088 doi: 10.1158/2159-8290.CD-15-0224
Di Mitri, D. et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156–2168 (2019).
pubmed: 31433989 pmcid: 6715643 doi: 10.1016/j.celrep.2019.07.068
Gil, V. et al. HER3 is an actionable target in advanced prostate cancer. Cancer Res. 81, 6207–6218 (2021).
pubmed: 34753775 pmcid: 8932336 doi: 10.1158/0008-5472.CAN-21-3360
Wang, L. et al. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 13, 201 (2015).
pubmed: 26297150 pmcid: 4546313 doi: 10.1186/s12916-015-0442-0
Olmos, D. et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 13, 1114–1124 (2012).
pubmed: 23059046 pmcid: 4878433 doi: 10.1016/S1470-2045(12)70372-8
Maxwell, P. J. et al. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur. Urol. 64, 177–188 (2013).
pubmed: 22939387 doi: 10.1016/j.eururo.2012.08.032
Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
pubmed: 18555777 doi: 10.1016/j.cell.2008.03.038
Toso, A. et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9, 75–89 (2014).
pubmed: 25263564 doi: 10.1016/j.celrep.2014.08.044
Armstrong, C. W. D. et al. Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. NAR Cancer 2, zcaa012 (2020).
pubmed: 32743555 pmcid: 7380483 doi: 10.1093/narcan/zcaa012
Katoh, H. et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24, 631–644 (2013).
pubmed: 24229710 pmcid: 3928012 doi: 10.1016/j.ccr.2013.10.009
Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra267 (2014).
doi: 10.1126/scitranslmed.3007974
Cesano, A. nCounter
pubmed: 26674611 pmcid: 4678588 doi: 10.1186/s40425-015-0088-7
Fenor de la Maza, M. D. et al. Immune biomarkers in metastatic castration-resistant prostate cancer. Eur. Urol. Oncol. 5, 659–667 (2022).
pubmed: 35491356 doi: 10.1016/j.euo.2022.04.004
Proudfoot, A. E. I. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol. 2, 106–115 (2002).
pubmed: 11910892 pmcid: 7097668 doi: 10.1038/nri722
Eash, K. J., Greenbaum, A. M., Gopalan, P. K. & Link, D. C. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 120, 2423–2431 (2010).
pubmed: 20516641 pmcid: 2898597 doi: 10.1172/JCI41649
Matsusaka, T. et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl Acad. Sci. USA 90, 10193–10197 (1993).
pubmed: 8234276 pmcid: 47740 doi: 10.1073/pnas.90.21.10193
Stein, B., Cogswell, P. C. & Baldwin, A. S. Jr Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol. Cell. Biol. 13, 3964–3974 (1993).
pubmed: 8321203 pmcid: 359940
Burke, S. J. et al. NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription. Am. J. Physiol. Endocrinol. Metab. 306, E131–E149 (2014).
pubmed: 24280128 doi: 10.1152/ajpendo.00347.2013
Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).
pubmed: 32086381 pmcid: 7219211 doi: 10.1126/sciimmunol.aay6017
Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).
pubmed: 31061129 pmcid: 6561293 doi: 10.1073/pnas.1902651116
He, M. X. et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat. Med. 27, 426–433 (2021).
pubmed: 33664492 pmcid: 7960507 doi: 10.1038/s41591-021-01244-6
Song, H. et al. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat. Commun. 13, 141 (2022).
pubmed: 35013146 pmcid: 8748675 doi: 10.1038/s41467-021-27322-4
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl. J. Med. 371, 1028–1038 (2014).
pubmed: 25184630 doi: 10.1056/NEJMoa1315815
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).
pubmed: 26510020 pmcid: 5228595 doi: 10.1056/NEJMoa1506859
Welti, J. et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clin. Cancer Res. 24, 3149–3162 (2018).
pubmed: 29555663 doi: 10.1158/1078-0432.CCR-17-3571
Sharp, A. et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Investig. 129, 192–208 (2019).
pubmed: 30334814 doi: 10.1172/JCI122819
Schaefer, C. F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674–D679 (2009).
pubmed: 18832364 doi: 10.1093/nar/gkn653
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Li, Y. et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci. Transl. Med. 11, eaax0428 (2019).
pubmed: 31801883 pmcid: 7238624 doi: 10.1126/scitranslmed.aax0428
Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
pubmed: 27381735 pmcid: 4935811 doi: 10.1038/ncomms12150
Tonnessen-Murray, C. A., Lozano, G. & Jackson, J. G. The regulation of cellular functions by the p53 protein: cellular senescence. Cold Spring Harb. Perspect. Med. 7, a026112 (2017).
pubmed: 27881444 pmcid: 5287062 doi: 10.1101/cshperspect.a026112
Razavipour, S. F., Harikumar, K. B. & Slingerland, J. M. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res. 80, 3451–3458 (2020).
Rajagopalan, L. & Rajarathnam, K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J. Biol. Chem. 279, 30000–30008 (2004).
pubmed: 15133028 doi: 10.1074/jbc.M313883200
Nasser, M. W. et al. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol. 183, 3425–3432 (2009).
pubmed: 19667085 doi: 10.4049/jimmunol.0900305
Moussouras, N. A. et al. Differences in sulfotyrosine binding amongst CXCR1 and CXCR2 chemokine ligands. Int. J. Mol. Sci. 18, 1894 (2017).
pubmed: 28869519 pmcid: 5618543 doi: 10.3390/ijms18091894
Ferraldeschi, R. et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol. 67, 795–802 (2015).
pubmed: 25454616 pmcid: 4410287 doi: 10.1016/j.eururo.2014.10.027
Rescigno, P. et al. Characterizing CDK12-mutated prostate cancers. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-20-2371 (2020).
doi: 10.1158/1078-0432.Ccr-20-2371 pubmed: 32988971 pmcid: 7855716
Migliozzi, D. et al. Microfluidics-assisted multiplexed biomarker detection for in situ mapping of immune cells in tumor sections. Microsyst. Nanoeng. 5, 59 (2019).
pubmed: 31700674 pmcid: 6831597 doi: 10.1038/s41378-019-0104-z
Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7, 1006–1017 (2017).
pubmed: 28450425 pmcid: 6143169 doi: 10.1158/2159-8290.CD-17-0261
Hothorn, T. & Lausen, B. On the exact distribution of maximally selected rank statistics. Comput. Stat. Data Anal. 43, 121–137 (2003).
doi: 10.1016/S0167-9473(02)00225-6
Lausen, B., Hothorn, T., Bretz, F. & Schumacher, M. Assessment of optimal selected prognostic factors. Biom. J. 46, 364–374 (2004).
doi: 10.1002/bimj.200310030

Auteurs

Christina Guo (C)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Adam Sharp (A)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Bora Gurel (B)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-5018-8078

Mateus Crespo (M)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-4043-8296

Ines Figueiredo (I)

The Institute of Cancer Research, London, UK.

Suneil Jain (S)

Northern Ireland Cancer Centre, Belfast, UK.
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Ursula Vogl (U)

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.

Jan Rekowski (J)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-5207-3864

Mahtab Rouhifard (M)

The Institute of Cancer Research, London, UK.

Lewis Gallagher (L)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-2694-3157

Wei Yuan (W)

The Institute of Cancer Research, London, UK.

Suzanne Carreira (S)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-5077-5379

Khobe Chandran (K)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Alec Paschalis (A)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Ilaria Colombo (I)

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
ORCID: 0000-0002-0602-8667

Anastasios Stathis (A)

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.

Claudia Bertan (C)

The Institute of Cancer Research, London, UK.

George Seed (G)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-1105-1781

Jane Goodall (J)

The Institute of Cancer Research, London, UK.

Florence Raynaud (F)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-0957-6279

Ruth Ruddle (R)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0003-0025-8872

Karen E Swales (KE)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-6572-1293

Jason Malia (J)

The Institute of Cancer Research, London, UK.

Denisa Bogdan (D)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-3017-4832

Crescens Tiu (C)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.
ORCID: 0000-0002-0515-6130

Reece Caldwell (R)

The Royal Marsden NHS Foundation Trust, London, UK.

Caterina Aversa (C)

The Royal Marsden NHS Foundation Trust, London, UK.

Ana Ferreira (A)

The Institute of Cancer Research, London, UK.

Antje Neeb (A)

The Institute of Cancer Research, London, UK.

Nina Tunariu (N)

The Royal Marsden NHS Foundation Trust, London, UK.

Daniel Westaby (D)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Juliet Carmichael (J)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Maria Dolores Fenor de la Maza (MD)

The Institute of Cancer Research, London, UK.
The Royal Marsden NHS Foundation Trust, London, UK.

Christina Yap (C)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0002-6715-2514

Ruth Matthews (R)

The Institute of Cancer Research, London, UK.

Hannah Badham (H)

The Institute of Cancer Research, London, UK.

Toby Prout (T)

The Institute of Cancer Research, London, UK.

Alison Turner (A)

The Institute of Cancer Research, London, UK.

Mona Parmar (M)

The Institute of Cancer Research, London, UK.
ORCID: 0000-0001-7818-4100

Holly Tovey (H)

The Institute of Cancer Research, London, UK.

Ruth Riisnaes (R)

The Institute of Cancer Research, London, UK.

Penny Flohr (P)

The Institute of Cancer Research, London, UK.

Jesus Gil (J)

MRC London Institute of Medical Sciences (LMS), London, UK.
Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.
ORCID: 0000-0002-4303-6260

David Waugh (D)

Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
Centre for Cancer Biology, University of South Australia, Adelaide, South Australia, Australia.

Shaun Decordova (S)

The Institute of Cancer Research, London, UK.

Anna Schlag (A)

The Institute of Cancer Research, London, UK.

Bianca Calì (B)

Institute of Oncology Research, Bellinzona, Switzerland.

Andrea Alimonti (A)

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland.
Institute of Oncology Research, Bellinzona, Switzerland.
Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland.
Department of Medicine, Veneto Institute of Molecular Medicine, University of Padova, Padua, Italy.
ORCID: 0000-0002-9362-2313

Johann S de Bono (JS)

The Institute of Cancer Research, London, UK. johann.debono@icr.ac.uk.
The Royal Marsden NHS Foundation Trust, London, UK. johann.debono@icr.ac.uk.
ORCID: 0000-0002-2034-595X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Locomotion › Taxie › Chimiotaxie › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigènes glycanniques associés aux tumeurs › Antigènes CD15 › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Cellules › Cellules myéloïdes › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Tissus › Glandes exocrines › Prostate › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Récepteurs cytoplasmiques et nucléaires › Récepteurs aux androgènes › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Antagonistes des androgènes › Antagonistes du récepteur des androgènes › Targeting myeloid chemotaxis to reverse...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Targeting myeloid chemotaxis to reverse...